Project Grant R03CA303904
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $164K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research aimed at "Deciphering the Structural Determinants of Response and Resistance to HER2-Targeted Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors for HER2-Mutant Non-Small Cell Lung Cancer". The research seeks to better understand the structural factors that influence sensitivity...
- This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...
- This $2,638,738.00 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand how aging increases the metastatic competence of the omentum, a fatty tissue that is a common site of metastasis in ovarian cancer. The research aims to identify the mechanisms by which aging increases the accumulation of immunosuppressive innate-like B cells in the omentum, and to develop strategies to decrease the metastatic competence of the omentum...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,916.00 to the University of Massachusetts Medical School to investigate factors contributing to chemoresistance in BRCA mutant hereditary breast and ovarian cancers. The overall goal is to gain a new understanding of the mechanisms behind chemoresistance in these cancers, which frequently develop resistance to existing chemotherapies and PARP inhibitors. The research aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore (UMB) to conduct research on the mechanisms by which chemotherapy can inadvertently promote metastasis in epithelial ovarian cancer. The research aims to determine how clinically approved chemotherapies activate tumor-associated membrane-anchored serine proteases (MASPs) in a way that potentiates tumor dissemination and metastatic...
- This Project Grant award of $420,400 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by the University of Texas MD Anderson Cancer Center to explore cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors in MTAP-loss tumor cells. The research aims to address the challenge of innate and acquired resistance observed in 40-60% and 20-30% of MTAP-loss cancer patients, respectively, when treated with these novel...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- The federal Project Grant award, valued at $1,690,396.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports epigenetic research on BRAF-mutant colorectal cancers at The University of Texas MD Anderson Cancer Center. The research aims to investigate the epigenetic mechanisms and targeting approaches during the response to BRAF inhibitor and anti-EGFR therapy for BRAF-mutant colorectal cancers. The award period runs from...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $421,204 to The University of Texas MD Anderson Cancer Center to conduct research on "Platelet Pathophysiology in Resistance to Antiangiogenic Therapy Against Ovarian Cancer Evaluated in a Vascularized TME-Chip." The award period runs from August 1, 2024 to July 31, 2028. The research aims to advance understanding of how platelets contribute to...